US 6,551,616 B1 · Extended release formulations of erythromycin derivatives

Abstract

Disclosed is a pharmaceutical composition for extended release of an erythromycin derivative in the gastrointestinal environment. The composition comprises an erythromycin derivative and a pharmaceutically acceptable polymer so that, when ingested orally, the composition induces statistically significantly lower Cmax in the plasma than an immediate release composition of the erythromycin derivative while maintaining bioavailability and minimum concentration substantially equivalent to that of the immediate release composition of the erythromycin derivative upon multiple dosing. The compositions of the invention have an improved taste profile and reduced gastrointestinal side effects as compared to those for the immediate release composition.

Claims4

Dependent claims

A method of reducing gastrointestinal adverse side effects comprising administering an effective amount of an extended release pharmaceutical composition comprising an erythromycin derivative and a pharmaceutically acceptable polymer.

Dependencies are inferred from the claim text.

Facts

Application

09/416,916Filed 13 Oct 1999 · continuation in part

Priority

11 Apr 1997

Granted

22 Apr 2003

Term ends

Not estimatedThe source records don’t support an estimate.

Classification8 codes

A61K 31/7048
Compounds having saccharide radicals and heterocyclic rings: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin,…
A61K 9/2054
Polysaccharides, e.g. alginate, gums; Cyclodextrin: cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
A61K 9/28
Pills, tablets, discs, rods: dragees; Coated pills or tablets , e.g. with film or compression coating
A61P 31/00
Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Extended release formulations of erythromycin derivatives

Life of this patent

Extended release formulations of erythromycin derivatives

Life of this patent

Abstract

Claims4